Galectin Therapeutics Inc.GALTNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
9.23%
↑ 394% above average
Average (39q)
-3.14%
Historical baseline
Range
High:46.24%
Low:-81.21%
CAGR
-2.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 9.23% |
| Q2 2025 | 41.43% |
| Q1 2025 | 36.46% |
| Q4 2024 | -37.08% |
| Q3 2024 | 19.71% |
| Q2 2024 | -17.03% |
| Q1 2024 | -0.91% |
| Q4 2023 | -4.31% |
| Q3 2023 | -1.81% |
| Q2 2023 | 12.95% |
| Q1 2023 | 2.74% |
| Q4 2022 | -30.92% |
| Q3 2022 | 15.94% |
| Q2 2022 | 2.75% |
| Q1 2022 | -33.80% |
| Q4 2021 | 9.93% |
| Q3 2021 | -0.62% |
| Q2 2021 | -29.70% |
| Q1 2021 | 19.34% |
| Q4 2020 | -32.16% |
| Q3 2020 | 2.88% |
| Q2 2020 | -70.26% |
| Q1 2020 | 30.92% |
| Q4 2019 | -81.21% |
| Q3 2019 | 5.20% |
| Q2 2019 | -27.59% |
| Q1 2019 | 20.70% |
| Q4 2018 | -11.38% |
| Q3 2018 | 28.70% |
| Q2 2018 | 10.03% |
| Q1 2018 | -76.06% |
| Q4 2017 | 46.24% |
| Q3 2017 | 2.22% |
| Q2 2017 | 8.73% |
| Q1 2017 | -7.55% |
| Q4 2016 | -1.37% |
| Q3 2016 | 17.97% |
| Q2 2016 | 18.83% |
| Q1 2016 | -45.51% |
| Q4 2015 | 20.61% |